Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials

被引:49
|
作者
Alosh, Mohamed [1 ]
Huque, Mohammad F. [2 ]
Bretz, Frank [3 ,4 ]
D'Agostino, Ralph B., Sr. [5 ]
机构
[1] US FDA, Div Biometr 3, Off Biostat, OTS,CDER, Silver Spring, MD 20993 USA
[2] US FDA, Off Biostat, OTS, CDER, Silver Spring, MD 20993 USA
[3] Novartis, Stat Methodol & Consulting, Basel, Switzerland
[4] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
[5] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA
关键词
negative subgroup treatment effect; treatment-by-subgroup interaction; supportive subgroup findings; targeted subgroup; MULTIPLE END-POINTS; SEVERE SEPSIS; DESIGN; ENRICHMENT; ALPHA; CONSISTENCY; FRAMEWORK; EFFICACY; CANCER;
D O I
10.1002/sim.7167
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clinical trials target patients who are expected to benefit from a new treatment under investigation. However, the magnitude of the treatment benefit, if it exists, often depends on the patient baseline characteristics. It is therefore important to investigate the consistency of the treatment effect across subgroups to ensure a proper interpretation of positive study findings in the overall population. Such assessments can provide guidance on how the treatment should be used. However, great care has to be taken when interpreting consistency results. An observed heterogeneity in treatment effect across subgroups can arise because of chance alone, whereas true heterogeneity may be difficult to detect by standard statistical tests because of their low power. This tutorial considers issues related to subgroup analyses and their impact on the interpretation of findings of completed trials that met their main objectives. In addition, we provide guidance on the design and analysis of clinical trials that account for the expected heterogeneity of treatment effects across subgroups by establishing treatment benefit in a pre-defined targeted subgroup and/or the overall population. Copyright (C) 2016 John Wiley & Sons, Ltd.
引用
收藏
页码:1334 / 1360
页数:27
相关论文
共 50 条
  • [21] Statistical planning in confirmatory clinical trials with multiple treatment groups, multiple visits, and multiple endpoints
    Sun, Hengrui
    Snyder, Ellen
    Koch, Gary G.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2018, 28 (01) : 189 - 211
  • [22] Role of clinical evaluation committees in sepsis trials: from 'valid cohort' assessment to subgroup analysis
    Dhainaut, Jean-Francois
    CRITICAL CARE, 2009, 13 (02):
  • [23] Multiplicity considerations for subgroup analysis subject to consistency constraint
    Alosh, Mohamed
    Huque, Mohammad F.
    BIOMETRICAL JOURNAL, 2013, 55 (03) : 444 - 462
  • [24] How to Conduct Clinical Trials in Children: A Tutorial
    Shakhnovich, Valentina
    Hornik, Christoph P.
    Kearns, Gregory L.
    Weigel, Jaylene
    Abdel-Rahman, Susan M.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, 12 (03): : 218 - 230
  • [25] Practical Considerations for Subgroups Quantification, Selection and Adaptive Enrichment in Confirmatory Trials
    Lin, Jianchang
    Bunn, Veronica
    Liu, Rachael
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2019, 11 (04): : 407 - 418
  • [26] Statistical considerations on implementing the MCP-Mod method for binary endpoints in clinical trials
    Chen, Jingjing
    Liu, Tina
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 19
  • [27] Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials
    van Doormaal, Frederiek F.
    Raskob, Gary E.
    Davidson, Bruce L.
    Decousus, Herve
    Gallus, Alexander
    Lensing, Anthie W. A.
    Piovella, Franco
    Prins, Martin H.
    Buller, Harry R.
    THROMBOSIS AND HAEMOSTASIS, 2009, 101 (04) : 762 - 769
  • [28] Statistical aspects of design and analysis of clinical trials for the prevention of caries
    Burnside, G.
    Pine, C. M.
    Williamson, P. R.
    CARIES RESEARCH, 2006, 40 (05) : 360 - 365
  • [29] Statistical considerations for vaccine immunogenicity trials Part 1: introduction and bioassay design and analysis
    Plikaytis, BD
    Carlone, GM
    VACCINE, 2005, 23 (13) : 1596 - 1605
  • [30] Adjusted significance levels for subgroup analyses in clinical trials
    Spiessens, Bart
    Debois, Muriel
    CONTEMPORARY CLINICAL TRIALS, 2010, 31 (06) : 647 - 656